Iovance Biotherapeutics Inc Aktie News

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ:IOVA). The investigation concerns whether Iovance and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON IOVANCE BIOTHERAPEUT...

SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), investors watched the company's shares plunge nearly 44% on May 9, 2025, after the San Carlos-based cell therapy pioneer reported a first-quarter revenue miss that sharply contradicted earlier upbeat assurances from management.

Iovance Biotherapeutics' stock plummeted 45% after a Q1 earnings miss, driven by temporary manufacturing issues and reduced revenue guidance. Management expects a rebound in Q2 with resumed full manufacturing capacity and increased commercial infusions, potentially leading to a positive earnings surprise. Despite the Q1 setback, Iovance's early adoption, expanding treatment network, and interna...

Think of some of the biggest and most successful stocks on the market. Now, go back 20 or 30 years.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IOVANCE BIOTHERAPEUTICS, INC. (IOVA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTE...

SAN FRANCISCO--(BUSINESS WIRE)--In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), investors watched the company's shares plunge nearly 44% on May 9, 2025, after the San Carlos-based cell therapy pioneer reported a first-quarter revenue miss that sharply contradicted earlier upbeat assurances from management. Hagens Berman is now investigating whether Iovance violated U.S. sec...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON IOVANCE BIOTHERAPEUTICS, INC. (IOVA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAI...